Pfizer Grant Programs

Pfizer releases requests for proposals on a regular basis, with a focus on financing research and development projects regarding specific health related topics. This includes projects concerning research, quality improvement or education, which aims to improve patient outcomes in areas of unmet medical need in-line with Pfizer’s strategy. Each tender includes a description of the area of interest, type of activities and deadlines. Check out the Pfizer Grant Programs below.

Pfizer – Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain

Budget: Max. $200,000 per project.

Total Budget: $1M

Funding Rate: 100%

Deadlines: 19 March / 18 June / 20 August (open until budget depleted)

Consortium: No country limitation. Open to medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other healthcare related entities. The project can include multiple partners if they all play a relevant role.

Scope: This grant is provided by Pfizer and Lilly. There remains a significant unmet need in the management of osteoarthritis (OA) and chronic pain associated with OA. With the lack of live conferences during the pandemic, this request for proposals intends to support virtual and potentially live programs and other innovative digital medical education for Health Care Providers. The focus is on Osteoarthritis and Chronic Pain associated with OA and patient-centred standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management.

Pfizer – 2021 Growth Hormone Research

Budget: $75,000 per project.

Funding Rate: 100%

Deadline: 1 June 2021

Consortium: All countries except USA (separate call for US applicants).

The applicant must have a medical or postdoctoral degree, an advanced nursing degree, or a degree in Pharmacy, Physiotherapy, or Social Work, and be affiliated to a host institution.

Scope: Research projects that will be considered for Pfizer support should advance medical knowledge of short stature. Pfizer will not supply the study drug.

Projects submitted may include:

Morbidities in growth disorders;
Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat growth disorders;
Comparative pathophysiology of daily vs long-acting growth hormone;
Innovative methods to evaluate levels of adherence of daily and long-acting growth hormone treatment;
Novel strategies to address current unmet medical needs in short stature management which could be addressed with long-acting growth hormone treatment.

Pfizer – Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease

Budget: $50,000 per project (Estimated Total budget: $150,000)

Funding Rate: 100%

Deadlines: 1 June 2021

Scope: Pfizer will consider projects focusing on preparing and/or optimizing multidisciplinary care teams for the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. Support is available for the development of leadership, best practices, SOP development, site readiness, support and/or training of HCPs within a multidisciplinary team environment to optimize the quality of care for patients who have/will have gene therapy in their treatment armamentarium.

Projects that address recombinant adeno-associated virus gene therapy in Rare Disease and are therapeutic area and disease area agnostic (i.e., platform) will be prioritized.

Clinical research projects will not be supported, nor will projects evaluating the efficacy of therapeutic or diagnostic agents be considered.

Get funding updates with Catalyze Alerts

Staying up-to-date on funding programs is important, but takes a lot of time. With Catalyze Alerts you will receive all relevant updates on upcoming funds: Horizon Europe, but also EIC and Eurostars 2021.

Subscribe to Catalyze Alerts